Seventeen neonates received an intravenous infusion of prostaglandin E. for an average of 39 days (range 8 to 104). Seven (group 1) had transposition of the great arteries with no ventricular septal defect or a small one; eight (group 2) had ductus-dependent pulmonary flow (pulmonary atresia or stenosis in six and tricuspid atresia in two); and two (group 3) had aortic coarctation, one with no ventricular septal defect, the other with ventricular septal defect, isthmus hypoplasia and descending aortic flow supplied mainly by the ductus.
An increase in the arterial partial pressure of oxygen (Po 2 ) was seen in groups 1 and 2. Six patients from group 1 and two from group 2 developed heart failure; cortical Type E prostaglandins have become a major advance in the management of neonates with certain critical heart defects (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Their administration to maintain ductus arteriosus patency has been, in general, restricted to short periods (1) (2) (3) (4) (5) (6) (7) (8) . Although the short-term use in the newborn period appears to be well established, the experience with the prolonged use has been limited and the indications for therapy unclear (9) (10) (11) (12) (13) (14) (15) (16) (17) . Our experience with the prolonged infusion of prostaglandin E, (Upjohn Company) in infants with congenital heart defects is presented in this report.
Methods
Patients. The study group comprised the 17 neonates who were treated with prostaglandin E, for a mean duration of 39 days (range 8 to 104) at our hospital from September 1979 to April 1983 (Table I) . Seven patients (group I) had transposition of the great arteries and intact ventricular septum or small septal defect; eight patients (group 2) had hyperostosis of long bones was seen in three patients from group 1 and three from group 2; one from group 1 had refractory diarrhea. Other side effects seen at the beginning improved as the rate of infusion diminished. In group 3, the patient with complex coarctation had a decrease in blood pressure in the arms, an increase in pressure in the legs and restoration of renal function; in the patient with no ventricular septal defect, heart failure worsened during therapy. Histologic changes seen in three ductus were attributed to the closing process.
When delaying surgery in selected ill infants with heart defects is deemed advantageous, long-term infusions of prostaglandin E. are feasible.
ductus-dependent pulmonary blood flow (pulmonary atresia or critical stenosis in six and tricuspid atresia in two); and two patients (group 3) had aortic coarctation, one with intact ventricular septum, the other with septal defect, isthmus hypoplasia and blood flow to the descending aorta supplied mainly by the ductus arteriosus.
Prostaglandin infusions. The prostaglandin infusion was maintained whenever it proved beneficial and it was deemed advantageous to delay surgical therapy beyond neonatal age. It was discontinued when no hemodynamic improvement could be proven, when there were persistent side effects (cortical hyperostosis) or when successful surgery was accomplished.
Prostaglandin E, was given intravenously at an initial rate of 0.05j.Lg/kg per min or less, and subsequently decreased to the lowest effective dose. In six patients from group I, the infusion was started after cardiac catheterization because a satisfactory arterial oxygenation was not achieved after balloon septostomy; in one patient, the infusion was started before ballooning. In group 2, prostaglandin E, was started as soon as ductus-dependent pulmonary blood flow was suspected, even before confirmatory cardiac catheterization. In group 3, the infusion was started after catheterization.
Clinical and laboratory data. Arterial blood gases, blood pressure, temperature, heart rate and respiratory rate deter- 
Results
Group 1: transposition of great arteries. In these patients, the arterial partial pressure of oxygen (Po 2 ) increased from a mean preinfusion level of 27 torr (range 22 to 32) to a mean postinfusion level of 40 torr (range 31 to 48) that was elevated for the remainder of the therapy. The efficacy of prostaglandin E I was tested by occasional interruption of the infusion followed by a decrease in the arterial oxygen tension (Fig. I ).
Cardiomegaly and cardiac failure developed in six patients but promptly responded to medical treatment. Symmetric cortical hyperostosis of long bones was seen in three patients after 22, 25 and 84 days, respectively. The patients were irritable and had tenderness and swelling in the limbs. Typical radiologic appearance is seen in Figure 2 . One patient had refractory diarrhea requiring total parenteral nutrition for 34 days. There were other side effects seen at the beginning of the treatment similar to those reported previously (9, 18) . Seizure-like activity was seen in two patients, pyrexia in five and hypotension and mild diarrhea in one.
Blalock-Hanlon atrial septectomy was performed in four patients. In one, the infusion was necessary even after the septectomy; an aortopulmonary anastomosis was performed on the 50th day of prostaglandin E, therapy but the child did not survive surgery. Another patient underwent a modified Senning procedure on the 66th day of infusion and died on the first postoperative day. At autopsy, the ductus was 20 mm long and 9 mm wide; its internal diameter was 6 mm. The midportion had been surgically ligated. Microscopically , fibrinous deposits were seen on the endothelial surface; the intimal cushions were normal; the internal elastic layer was thin and large interruptions were seen at the level of the intimal cushions; the media showed clear spaces consistent with edema and no inner medial necrosis or fibrosis.
Group 2: ductus-dependent pulmonary blood flow. In these patients a sharp increase in arterial P0 2 to a mean level of 48 torr (range 39 to 56) from the pretreatment level of 30 torr (range 22 to 37) was observed (Fig. 3) . Adequate systemic arterial tension was maintained up to 64 days. In only two patients was cardiac decompensation seen. In two patients, mild cortical hyperostosis was detected radiologically on days 39 and 58, respectively. Side effects seen at the beginning were pyrexia in three patients, hypotension in two, apnea in one, rash in one, tachypnea in three, tachycardia and bradycardia in two and seizure-like activity in three.
Two patients (Cases 9 and 10) underwent pulmonary valvotomy, one dying at surgery. An aortopulmonary shunt was performed in six patients, two of whom died; the surgery was performed twice in both patients because of thrombus formation in the prosthetic tubing. Thrombosis was immediate in one (Case 14), and delayed in the other (Case 8). At autopsy, in Case 8 the ductus was 20 mm long, 3 mm wide externally and I mm wide internally; the lumen was covered by fibrinous material; the intimal cushions were thickened, fibrosed and circumferential; and the elastica was wavy with focal areas of fragmentation and duplication in contact with the intimal cushion but there was no interruption. No fibrosis or necrosis of the inner media or edema of the outer media was noted.
Group 3: aortic coarctation (Fig. 4) . In this group, the patient (Case 16) with complex coarctation (near arch interruption) had a decrease in blood pressure in the upper limbs, an increase in blood pressure in the legs and restoration of renal function while the infusion persisted. The infusion was stopped on the 38th day when subclavian flap angioplasty, pulmonary artery banding and ductus ligation were done. In the patient with an intact ventricular septum (Case 17), heart failure worsened and only cleared when the prostaglandin infusion was stopped, and marked systemic hypertension unresponsive to medical treatment fol- lowed. He died suddenly 2 weeks after prostaglandin E 1 had been discontinued. Postmortem examination revealed a patent ductus II mm long with an external diameter of 6 mm and an internal diameter of 2 mm. Microscopically, the intimal cushions were thickened, deformed and fibrosed, and fibrinous deposits were noted on the surface; the internal elastic layer was wavy with focal fragmentation and dupli-
Discussion
Morphologic changes in ductus after prolonged prostaglandin infusion. The long-term effectiveness of prostaglandin E 1 in maintaining ductus patency has been demonstrated previously (11, 12, 16, (17) (18) (19) (20) (21) . However, the fear of adverse effects may restrict its administration to short periods of time .
Potentially dangerous changes in the structure of the ductus have been attributed to prolonged use of prostaglandin E\. Cole et al. (17) described the ductus in an infant after 39 days of prostaglandin E\ therapy. It showed disruption of the internal elastic lamella; localized increase in the medial elastic tissue; areas of disarray and destruction of medial muscular fibers; medial elastic fragmentation, edema and cavitation; thickening and mononuclear cell infiltration of the adventitia at the ductus-pulmonary artery junction, the infiltration extending to the nerve trunks, which also displayed edema and cavitation; and generalized increase of cation, and areas of interruption were noted in contact with the intimal cushion; the inner media showed focal necrosis and fibrosis in continuity with the intimal cushion fibrosis at the level of the interrupted elastica; and there was edema of the outer media. mucopolysaccharides. Gittenberger-de Groot et al. (22) reported the histologic findings in four ductus after infusion of prostaglandin E, for 10 hours to 3 days. These consisted of medial edema and separation by clear spaces, interruptions of the internal elastic lamina and intimal lacerations, sometimes extending into the media.
In an extensive study to define the normal structure of the closing ductus, Silver et al. (23) examined 103 specimens from fetuses and newborn infants of different gestational ages, birth weights and diagnoses, including 17 with congenital heart defects who received prostaglandin E, over a period of 4 to 7 days. The lesions found in prostaglandin E,-treated and nontreated babies consisted of intimal fibrinous deposits, focal hemorrhages and dissecting aneurysms of differing degrees. Each of these lesions occurred in all groups with the exception of stillborns, who failed to show intimal fibrinous deposits or focal hemorrhages, and infants older than 3 weeks, who did not show dissecting aneurysms. No morphologic differences could be seen between the three types of lesions in the prostaglandin E)-treated and nontreated patients of the same age. The investigators concluded that the lesions were due not necessarily to the prostaglandin E, therapy, but to the ductus patency for whatever reason.
In three of our patients, the ductus was examined histologically. The changes found were: I) intimal cushion thickening and fibrosis in two; 2) internal elastic fragmentation and duplication in two, and interruption in one; and 3) medial edema, necrosis and fibrosis at the cushion level in two. These changes are also found in the normally closed ductus (23) and were not attributed to the prostaglandin therapy. No lacerations, hemorrhage or aneurysms that could predispose to ductal rupture were found. Similarly, Park et al. (24) found no significant deleterious morphologic changes after prostaglandin E, infusion.
Symmetric laminar cortical hyperostosis oflong bones of the limbs. This adverse effect was seen in five patients, accompanied by swelling and tenderness in three and detected radiologically only in two. This phenomenon, not previously reported from North America, has been seen in Japan in association with long-term infusion of low dose prostaglandin E, (13, 21) . These changes in the limbs resemble those of Caffey's disease, but the conspicuous absence of involvement of the mandible, the minimal or no involvement of the clavicles and the symmetry of the lesions are in sharp contrast with this disease. Prostaglandins of the E series are potent local mediators of bone resorption; furthermore, prostaglandin synthesis is necessary for the production of osteoclast-activating factor by normal human peripheral blood leukocytes (25) . The stimulation of bone resorption by the E prostaglandins varies in a bell-shaped way as the prostaglandin concentration increases (26) . As suggested by Dekel and Francis (27) , it is possible that the same prostaglandin at a higher concentration stimulates bone formation. Why the local effects are more prevalent in the long bones of the limbs is uncertain.
Other side effects. These occurred at the beginning of therapy and lessened when the rate of infusion was decreased. These adverse reactions may also occur during short-term therapy, and have been reported previously elsewhere (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Heart failure due to the prolonged added ductus flow was seen in some of our patients. Although in patients with transposition or ductus-dependent pulmonary blood flow, heart failure was easily managed medically or with a decrease in the prostaglandin E] infusion, in patients with simple coarctation improvement was only achieved after the infusion was discontinued.
Conclusions. The ductus responsiveness to prostaglandin E) persists for many weeks. Adverse effects are seen mostly at the beginning of the therapy, are dose-related and reverse promptly when the treatment is stopped or the dose is decreased. Symmetric cortical hyperostosis of long bones may be seen after 3 weeks of therapy. It also appears to be dose-related, taking longer to manifest when smaller doses are used. It reverses spontaneously, clinically and radiologically, when the treatment is discontinued. Morphologic changes observed in the ductus are likely related to the normal closing process, not to the use of prostaglandin. When it is deemed advantageous to delay surgery in selected critically ill infants with congenital heart defects, long-term infusions of prostaglandin E] are feasible.
